Abstract
New advances in cancer immunotherapy have been flooding the market at a rapid rate. Pembrolizumab (Keytruda), a programmed cell death protein 1 inhibitor, introduced in 2014, has been used to treat several cancers. Immune-related adverse events associated with pembrolizumab and other immune checkpoint inhibitors are now well-described complications. We describe the case of a 65-year old female with severe oral lichenoid lesions occurring after treatment with pembrolizumab for bladder cancer. To the best of our knowledge, this is the first report of a biopsy-proven oral erosive lichenoid reaction confirmed through direct immunofluorescence.
Original language | English (US) |
---|---|
Pages (from-to) | e301-e307 |
Journal | Oral surgery, oral medicine, oral pathology and oral radiology |
Volume | 130 |
Issue number | 5 |
DOIs | |
State | Published - Nov 2020 |
All Science Journal Classification (ASJC) codes
- Surgery
- Oral Surgery
- Pathology and Forensic Medicine
- Dentistry (miscellaneous)
- Radiology Nuclear Medicine and imaging